Skip to content
FORSIDEN
Log ind Opret konto
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2026

Genmab — Februar 2026

Planlagt Fastgjort Låst Flyttet Genmab
385 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • W Offline
    W Offline
    w
    wrote on sidst redigeret af
    #346

    Er det
    fordi 3. linie i epco og 2. Line tivdak ikke har flere patienter

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #347

      yes, that is the reason why growth will slow, but from 67% to 11.5% is a big drop, also given the approval of 2nd line FL and the constant focus on community centers with the subcutaneaous formulation, where i had hoped additional growth could come from

      1 Reply Last reply
      0
      • StockBullS Offline
        StockBullS Offline
        StockBull
        wrote on sidst redigeret af
        #348

        Marts er ofte en relativt sløv periode. Jeg holder derfor tørt krudt på sidelinjen og venter på et potentielt pull-back (f.eks. mod 1.780–1.820 eller RSI <27–30 på daily), før jeg overvejer yderligere supplering. Det giver bedre risk/reward før eventuel opgang i april/maj.

        1 Reply Last reply
        0
        • StockBullS Offline
          StockBullS Offline
          StockBull
          wrote on sidst redigeret af
          #349

          skulle være 1.720–1.780

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #350

            Tepkinly – Epcoritamab - on the EMA CHMP agenda: Scope: Extension of indication to include in combination with rituximab and lenalidomide treatment of patients with relapsed/refractory follicular lymphoma (FL) for Tepkinly https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-23-26-february-2026_en.pdf

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #351

              NICE Recommends TEPKINLY®▼ (epcoritamab), a Subcutaneous Bispecific Antibody for Adults With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) After Two or More Lines of Systemic Therapy https://www.abbvie.co.uk/media/nice-recommends-tepkinly-epcoritamab-a-subcutaneous-bispecific-antibody-for-adults-with-relapsed-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy.html

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #352

                so the UK is behind, but the EU extension mentioned above is also under review in UK for publication date Sep26

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #353

                  RAINFOL-02 goes to Active, not recruiting https://clinicaltrials.gov/study/NCT06619236?tab=history&a=16&b=17#version-content-panel

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #354

                    innovaTV 301 Completed

                    1 Reply Last reply
                    0
                    • R Offline
                      R Offline
                      Raun
                      wrote on sidst redigeret af
                      #355

                      Genmab Buyback And Abkinley Approval Reframe Growth And Risk Balance https://finance.yahoo.com/news/genmab-buyback-abkinley-approval-reframe-050838816.html

                      1 Reply Last reply
                      0
                      • B Offline
                        B Offline
                        bikube
                        wrote on sidst redigeret af
                        #356

                        Godt at få deres syn på sagen også.

                        1 Reply Last reply
                        0
                        • N Offline
                          N Offline
                          npo
                          wrote on sidst redigeret af
                          #357

                          @Raun 17:07 - tak for link/
                          heads-up

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #358

                            Godmorgen 🙂

                            1 Reply Last reply
                            0
                            • L Offline
                              L Offline
                              LP90
                              wrote on sidst redigeret af
                              #359

                              Godmorgen 🙂

                              1 Reply Last reply
                              0
                              • B Offline
                                B Offline
                                bibob
                                wrote on sidst redigeret af
                                #360

                                God morgen. 🙂

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #361

                                  Link Preview Image
                                  Genmab trak stikket på blockbusterdrøm – nu viser andre selskaber interesse

                                  Genmab-topchef er overbevist om, at det tidligere spået blockbuster-håb acasunlimab ville have nået markedet, men konkurrencen gjorde det nødvendigt at droppe udviklingen, siger Jan van de Winkel.

                                  favicon

                                  (medwatch.dk)

                                  1 Reply Last reply
                                  0
                                  • S Offline
                                    S Offline
                                    Sukkeralf
                                    wrote on sidst redigeret af
                                    #362

                                    Ville da være dejligt hvis Genmab kunne skippe acasunlimab videre til et andet selskab

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #363

                                      does it mention what companies are
                                      showing interest?

                                      1 Reply Last reply
                                      0
                                      • G Offline
                                        G Offline
                                        gentogen
                                        wrote on sidst redigeret af
                                        #364

                                        No. Just now I was able to read the whole text. So try again. Jan mentions that they continue treating the patients enrolled in the phase 3.

                                        1 Reply Last reply
                                        0
                                        • G Offline
                                          G Offline
                                          gentogen
                                          wrote on sidst redigeret af
                                          #365

                                          It says that they have had "en del" henvendelser

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper